TNNT2 and breast cancer: In a cohort study of 87 patients treated with radiotherapy for breast cancer, lung cancer or mediastinal lymphoma, there was a downward trend in hs-cTnT from pre-radiotherapy to the completion of radiotherapy, especially in the subgroup that received an anthracycline and trastuzumab.